Advisory Board

Professor Filipe Cabreiro

Filipe Cabreiro, Ph.D. is Professor at the University of Cologne-CECAD and Associate Professor and Reader in the Institute of Clinical Sciences (ICS) at Imperial College London.

His research interests are in gut microbiota in metabolic disease and bacterial regulation of the effect of drugs and diet on host health and lifespan. Read Chemotherapy Modulation by a Cancer-Associated Microbiota Metabolite.

He is a biochemist, who has studied the biological mechanisms underlying molecular stress protection, metabolism, and aging. His seminal work led to a paradigm shift in the use of C. elegans for studying host-microbe-drug interactions throughout aging.

Read Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism, Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila, and Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans. Read Worms need microbes too: microbiota, health and aging in Caenorhabditis elegans and Anthranilate Fluorescence Marks a Calcium-Propagated Necrotic Wave That Promotes Organismal Death in C. elegans.

Filipe leads his Host-Microbe Co-Metabolism Research Group in his Cabreiro Lab. He focuses on the molecular mechanisms underlying metabolic diseases and aging. Read Role of gut microbiota on the onset of sarcopenia and C. elegans: A biosensor for host-microbe interactions.

The research focus of his lab revolves around deciphering the molecular intricacies underpinning metabolic disease, cancer, and aging, and recognizing their significant medical, social, and economic ramifications. Of particular interest is the burgeoning field of host-microbiota interactions, especially their impact on conditions like obesity, type-2 diabetes, and aging.

Watch Awakening Drugs by Feeding Bugs, The Microbiome and a Long Healthy Life, and How The Gut Microbiome Impacts Longevity. Read New insights into how diet and medication impact the influence of gut bacteria on our health.

Previously, for more than 10 years, Filipe was at the University College London (UCL) between 2008 and 2018.

First, he was Post-doctoral Research Fellow at the Institute of Healthy Ageing, UCL until 2013, and until 2018, a Lecturer and Assistant Professor in Metabolism and Metabolic Diseases in the Division of Bioscience, Institute of Structural and Molecular Biology, Institute of Healthy Ageing at UCL.

Filipe earned his Ph.D. in Biochemistry in 2008 from the Universite Paris Cite. He earned his Bachelor’s Degree of Applied Science in Applied Biochemistry in 2004 from the University of Porto, Portugal. He did his Erasmus Research Internship, Equivalent to French Masters in the Biology of Ageing at University Paris VII.

In 2019, he became a Member of the Advisory Board of Lancet Heathy Longevity and Reviews Commons, and is a Member of the American Federation for Aging Research (AFAR). He earned the EMBO Young Investigator Award for his work between 2017 and 2020.

He was awarded the Wellcome/Royal Society Sir Henry Dale Fellowship for his work at UCL between 2014 and 2019.

In 2017, Filipe was the Contender for the Blavatnik Award, and in 2016, he was awarded the Higher Education Academy (HEA) Fellowship.

Filipe was invited to be Speaker at the Cell Symposia on Multifaceted Mitochondria 2024 and Aging and Microbiome Conference 2024.

Watch Tweaking microbial metabolism with drugs to improve aging.

Listen to Microbial Interactions with Medications: Filipe Cabreiro Talks Drugs and the Microbiome.

Read Host-microbe-drug-nutrient screen identifies bacterial effectors of metformin therapy. Read Bioaccumulation of therapeutic drugs by human gut bacteria and Increased fidelity of protein synthesis extends lifespan.

Visit his LinkedIn profile, PubMed page, ResearchGate page, and Google Scholar page. Follow him on Loop, Twitter, and his Lab’s Twitter.